Investment Notes: Heidi Series B

Heidi is an ambient AI medical scribe that automates clinical documentation, reducing administrative burden and paving the way toward full workflow automation in healthcare.

We’re excited to back Heidi again in their Series B, alongside Point72 Private Investments and other leading global investors. Heidi has quickly become one of the fastest-growing companies in the Blackbird portfolio and is establishing itself as a category-defining business in healthcare AI.

The fastest growing company in the Blackbird portfolio

Heidi has been growing rapidly month-on-month over the past year, outpacing even our most bullish expectations from the previous round. By adoption and momentum, it now sits among the fastest-growing companies in the Blackbird portfolio, at a pace comparable to category-defining businesses like Canva at a similar stage.

Heidi now supports more than 2 million consultations every week with 70% of activity outside Australia across North America and Europe. Each week, millions of patient encounters now flow through Heidi, underscoring its relevance in daily clinical practice and its mission to reach patients by empowering clinicians.

Clinician advocacy is powering enterprise momentum

Heidi’s freemium model has created broad bottom-up adoption, with clinician advocacy now driving enterprise conversion at scale. Many enterprise accounts originated through direct-to-consumer referrals, where clusters of individual users generated inbound leads or senior leaders requested evaluation because “their clinicians are already using Heidi.”

This momentum has proven decisive against established incumbents. Several major health systems have replaced legacy documentation tools with Heidi after low adoption and limited clinician engagement. In other cases, departments have self-funded continued use after pilots, with organisations scaling Heidi across hundreds of physicians once frontline advocacy took hold.

Part of Heidi’s success is the tangible productivity it delivers. Clinicians using Heidi report saving more than an hour each day, giving hospitals and health systems line of sight to meaningful efficiency improvements and the potential to lift overall capacity by around 10%. Importantly, this momentum has not been driven by top-down sales, but by frontline doctors who have championed the product within their organisations.

While North America is a major focus, Heidi is also building a strong international footprint. In the UK, one in two two in three GPs use Heidi weekly. The team is expanding into Germany, France, and Spain — markets well suited to Heidi’s product-led growth motion. This geographic diversification not only reduces reliance on a single market but also opens up large addressable opportunities that US-focused competitors often overlook.

Product evolution toward an AI care partner

Heidi’s roadmap extends beyond transcription toward comprehensive workflow automation. The platform already generates notes in the clinician’s voice and automates follow-up actions such as referral letters and patient summaries. From there, Heidi is expanding into downstream tasks, including structured task lists, which in just eight weeks of release saw 45 million tasks created.

These steps both deepen value for current users and widen Heidi’s footprint within organisations. By owning the context of consultation notes, the platform is well placed to expand across multiple workflows and compound adoption from the ground up, moving beyond the promise of ambient AI. 

‍

Path to generational scale

We believe Heidi is on a credible path toward building a generational company in healthcare AI. The combination of rapid adoption, global expansion, and visionary product roadmap puts the company on track to become a cornerstone in the future of clinical practice.

We’re proud to support co-founders Dr Thomas Kelly, Waleed Mussa, Yu Liu, and the team as they continue to scale toward category leadership.

‍

‍

‍